Sol Gel Technologies Ltd
NASDAQ:SLGL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.366
1.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sol Gel Technologies Ltd
Sol Gel Technologies Ltd
Cash & Cash Equivalents
Sol Gel Technologies Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Cash & Cash Equivalents
$13.4m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cash & Cash Equivalents
₪101.1m
|
CAGR 3-Years
39%
|
CAGR 5-Years
97%
|
CAGR 10-Years
63%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cash & Cash Equivalents
$3.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-16%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Cash & Cash Equivalents
₪8.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
3%
|
CAGR 10-Years
57%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cash & Cash Equivalents
₪5.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-11%
|
|
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
See Also
What is Sol Gel Technologies Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
13.4m
USD
Based on the financial report for Sep 30, 2024, Sol Gel Technologies Ltd's Cash & Cash Equivalents amounts to 13.4m USD.
What is Sol Gel Technologies Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
12%
Over the last year, the Cash & Cash Equivalents growth was -5%. The average annual Cash & Cash Equivalents growth rates for Sol Gel Technologies Ltd have been -32% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
